Ze-bo Jiang

Zhuhai, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 39 publications

Epitranscriptomics, immunometabolism, and NETosis: unlocking novel mechanisms of traditional Chinese medicine in COPD.

Epitranscriptomics, immunometabolism, and NETosis: unlocking novel mechanisms of traditional Chinese medicine in COPD.

Journal: Frontiers in immunology
Published: June 09, 2026

Oxidative stress-driven epigenetic reprogramming of immune cells in COPD: from epitranscriptomic and metabolic crosstalk to treatable traits.

Oxidative stress-driven epigenetic reprogramming of immune cells in COPD: from epitranscriptomic and metabolic crosstalk to treatable traits.

Journal: Frontiers in immunology
Published: April 25, 2026

The Respiratory Epithelial Barrier as an Immunopharmacological Rheostat: From Homeostatic Sentinel to Therapeutic Target in Chronic Lung Disease.

The Respiratory Epithelial Barrier as an Immunopharmacological Rheostat: From Homeostatic Sentinel to Therapeutic Target in Chronic Lung Disease.

Journal: European journal of immunology
Published: January 09, 2026

Necroptosis in asthma: a critical driver of immune dysregulation and airway remodeling.

Necroptosis in asthma: a critical driver of immune dysregulation and airway remodeling.

Journal: Frontiers in immunology
Published: January 09, 2026

Disulfidptosis in chronic obstructive pulmonary disease: Unraveling a novel immunometabolic nexus for therapeutic targeting.

Disulfidptosis in chronic obstructive pulmonary disease: Unraveling a novel immunometabolic nexus for therapeutic targeting.

Journal: Respiratory medicine
Published: January 08, 2026

Cuproptosis: The metabolic-immune axis in chronic obstructive pulmonary disease pathogenesis and therapeutics.

Cuproptosis: The metabolic-immune axis in chronic obstructive pulmonary disease pathogenesis and therapeutics.

Journal: International immunopharmacology
Published: December 09, 2025

The gut-lung axis in COPD: immunomodulatory roles of gut microbiota and novel therapeutic strategies.

The gut-lung axis in COPD: immunomodulatory roles of gut microbiota and novel therapeutic strategies.

Journal: Frontiers in immunology
Published: October 28, 2025

Pyroptosis-immune cell cross talk in asthma: From molecular mechanisms to precision therapeutics.

Pyroptosis-immune cell cross talk in asthma: From molecular mechanisms to precision therapeutics.

Journal: Frontiers in immunology
Published: October 17, 2025

Ferroptosis-immune-metabolic axis in asthma: mechanistic crosstalk, endotype-specific regulation, and translational targeting.

Ferroptosis-immune-metabolic axis in asthma: mechanistic crosstalk, endotype-specific regulation, and translational targeting.

Journal: Frontiers in immunology
Published: October 14, 2025

Cepharanthine Reverses Gefitinib Resistance in NSCLC by Concurrently Inhibiting AKT/P70S6K Survival Signaling and Activating STING-Mediated Immune Response.

Cepharanthine Reverses Gefitinib Resistance in NSCLC by Concurrently Inhibiting AKT/P70S6K Survival Signaling and Activating STING-Mediated Immune Response.

Journal: Chemical biology & drug design
Published: September 02, 2025

Pyroptosis-driven immune dysregulation in COPD: molecular mechanisms and therapeutic implications.

Pyroptosis-driven immune dysregulation in COPD: molecular mechanisms and therapeutic implications.

Journal: Frontiers in immunology
Published: August 15, 2025

Plumbagin Triggers STING Pathway Activation to Suppress Non-Small Cell Lung Cancer Progression.

Plumbagin Triggers STING Pathway Activation to Suppress Non-Small Cell Lung Cancer Progression.

Journal: Chemical biology & drug design
Published: June 26, 2025
Showing 1-12 of 39

Last Updated: 09/26/2026